CSB work is profiled in MGH Research Institute spotlight "Mass General Researchers Investigate the ‘Big Eaters’ of the Immune System: #MacrophageMonday"
Checking out checkpoints: Immune checkpoint blockers (ICBs) are designed to activate the immune system against cancer. These drugs can be extraordinarily effective in some patients but not in others. Now, Mikael Pittet and colleagues have used molecular imaging to track ICBs in real time within tumors. Their study, published in Science Translational Medicine, uncovers a mechanism of treatment resistance, which can be overcome with additional chemical modifications. See also: the Journal Cover illustrating the “Tug-of-war with anti-PD-1” and interview with the authors. Abstract Reprint Full Text
Congratulations to Dr. Camilla Engblom, from the Pittet laboratory, for brillantly completing her PhD thesis work entitled “Cancer-host interactions influencing disease progression and therapy”. Dr. Engblom graduated from the PhD Program in Immunology at Harvard Medical School.
Today, the Swiss Cancer League awarded its most prestigious research prize to Dr. Mikael Pittet from the Center for System Biology at MGH, Boston. Dr. Pittet has done fundamental work in the field of immuno-therapies, in particular investigating the myeloid cells contribution. Immunotherapies - the treatments that support the body's immune system in the suppression of cancer cells - are a mainstream hope in the current fight against cancer.
This presentation of Mikael Pittet laboratory's latest work on cancer immunotherapy was given at the 2016 World Medical Innovation Forum.